Copyright
©The Author(s) 2022.
World J Clin Cases. Oct 6, 2022; 10(28): 10085-10096
Published online Oct 6, 2022. doi: 10.12998/wjcc.v10.i28.10085
Published online Oct 6, 2022. doi: 10.12998/wjcc.v10.i28.10085
Table 1 Hepatitis B virus DNA levels in chronic hepatitis B patients at weeks 168 and 192 (mean SD, log10IU/mL)
Group | HBeAg-positive | HBeAg-negative | ||||
Baseline | 168 wk | 192 wk | Baseline | 168 wk | 192 wk | |
A | 7.64 ± 1.01 | 1.18 ± 0.86 | 0.9 ± 0.96 | 6.22 ± 1.25 | 0.62 ± 0.66 | 0.35 ± 0.59 |
B | 7.65 ± 0.95 | 1.13 ± 0.82 | 1.02 ± 0.85 | 6.31 ± 1.37 | 0.36 ± 0.61 | 0.33 ± 0.57 |
P | 0.937 | 0.728 | 0.560 | 0.798 | 0.150 | 0.867 |
Table 2 Reduction of hepatitis B virus DNA levels of chronic hepatitis B patients at weeks 168 and 192 (mean SD, log10IU/mL)
Group | HBeAg-positive | HBeAg-negative | ||
168 wk | 192 wk | 168 wk | 192 wk | |
A | 6.44 ± 1.39 | 6.61 ± 1.28 | 5.73 ± 1.25 | 6.05 ± 1.20 |
B | 6.53 ± 1.24 | 6.69 ± 1.12 | 5.99 ± 1.47 | 6.03 ± 1.49 |
P | 0.654 | 0.696 | 0.533 | 0.952 |
Table 3 Characteristics of seven patients developing genotypic mutations to entecavir
Group A (entecavir) | Group B (entecavir maleate) | ||||||
Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | |
Age, yr | 32 | 34 | 28 | 29 | 43 | 34 | 21 |
Sex | Male | Male | Male | Male | Male | Male | Male |
Prior LAM exposure | Yes | Yes | No | No | Yes | Yes | No |
Prior ADV exposure | Yes | Yes | No | No | Yes | No | No |
Baseline | |||||||
HBeAg status | Positive | Positive | Positive | Positive | Positive | Positive | Positive |
HBV DNA, log10 IU/mL | 6.69 | 7.99 | 8.06 | 5.32 | 7.77 | 7.47 | 7.81 |
LAM resistance | No | No | No | No | No | Yes | No |
ADV resistance | Yes | Yes | No | No | Yes | No | No |
At maximum viral suppression | |||||||
wk | 24 | 48 | 72 | 84 | 48 | 12 | 120 |
HBV DNA, log10 IU/mL | 4.07 | 1.18 | 2.97 | 1.76 | 2.26 | 4.78 | TND |
At time of resistance confirmed | |||||||
wk | 144 | 144 | 144 | 144 | 144 | 144 | 144 |
HBV DNA, log10 IU/mL | 6.91 | 6.04 | 4.41 | 1.73 | 6.73 | 4.96 | 1.79 |
Mutational pattern | rtL180M | rtL180M | rtL180M | rtL180M | rtL180M | rtL180M | rtL180M |
rtS202G | rtS202G | rtS202G | rtV173L | rtT184S | rtS202G | rtT184S | |
rtM204V | rtM204V | rtM204V | rtM204V | rtM204V | rtM204V | rtM204V | |
rtM250V | |||||||
Addition of ADV | Yes | Yes | Yes | No | Yes | Yes | No |
HBV DNA, log10 IU/mL | |||||||
Week 168 | 5.14 | 5.08 | 3.18 | 1.84 | 3.43 | 4.86 | TND |
Week 192 | 4.2 | 2.77 | 3.1 | Missing | 2.89 | 4.28 | Missing |
- Citation: Xu JH, Wang S, Zhang DZ, Yu YY, Si CW, Zeng Z, Xu ZN, Li J, Mao Q, Tang H, Sheng JF, Chen XY, Ning Q, Shi GF, Xie Q, Zhang XQ, Dai J. One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C. World J Clin Cases 2022; 10(28): 10085-10096
- URL: https://www.wjgnet.com/2307-8960/full/v10/i28/10085.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i28.10085